Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 41

1.

Rational Zika vaccine design via the modulation of antigen membrane anchors in chimpanzee adenoviral vectors.

López-Camacho C, Abbink P, Larocca RA, Dejnirattisai W, Boyd M, Badamchi-Zadeh A, Wallace ZR, Doig J, Velazquez RS, Neto RDL, Coelho DF, Kim YC, Donald CL, Owsianka A, De Lorenzo G, Kohl A, Gilbert SC, Dorrell L, Mongkolsapaya J, Patel AH, Screaton GR, Barouch DH, Hill AVS, Reyes-Sandoval A.

Nat Commun. 2018 Jun 22;9(1):2441. doi: 10.1038/s41467-018-04859-5.

2.

Immobilization by Surface Conjugation of Cyclic Peptides for Effective Mimicry of the HCV-Envelope E2 Protein as a Strategy toward Synthetic Vaccines.

Meuleman TJ, Dunlop JI, Owsianka AM, van de Langemheen H, Patel AH, Liskamp RMJ.

Bioconjug Chem. 2018 Apr 18;29(4):1091-1101. doi: 10.1021/acs.bioconjchem.7b00755. Epub 2018 Feb 19.

3.

Reverse epitope mapping of the E2 glycoprotein in antibody associated hepatitis C virus.

Naik AS, Owsianka A, Palmer BA, O'Halloran CJ, Walsh N, Crosbie O, Kenny-Walsh E, Patel AH, Fanning LJ.

PLoS One. 2017 May 30;12(5):e0175349. doi: 10.1371/journal.pone.0175349. eCollection 2017.

4.

Conformational Flexibility in the Immunoglobulin-Like Domain of the Hepatitis C Virus Glycoprotein E2.

Vasiliauskaite I, Owsianka A, England P, Khan AG, Cole S, Bankwitz D, Foung SKH, Pietschmann T, Marcotrigiano J, Rey FA, Patel AH, Krey T.

MBio. 2017 May 16;8(3). pii: e00382-17. doi: 10.1128/mBio.00382-17.

5.

Full Genome Sequence and sfRNA Interferon Antagonist Activity of Zika Virus from Recife, Brazil.

Donald CL, Brennan B, Cumberworth SL, Rezelj VV, Clark JJ, Cordeiro MT, Freitas de Oliveira França R, Pena LJ, Wilkie GS, Da Silva Filipe A, Davis C, Hughes J, Varjak M, Selinger M, Zuvanov L, Owsianka AM, Patel AH, McLauchlan J, Lindenbach BD, Fall G, Sall AA, Biek R, Rehwinkel J, Schnettler E, Kohl A.

PLoS Negl Trop Dis. 2016 Oct 5;10(10):e0005048. doi: 10.1371/journal.pntd.0005048. eCollection 2016 Oct.

6.

Role of Conserved E2 Residue W420 in Receptor Binding and Hepatitis C Virus Infection.

Cowton VM, Angus AGN, Cole SJ, Markopoulou CK, Owsianka A, Dunlop JI, Gardner DE, Krey T, Patel AH.

J Virol. 2016 Jul 27;90(16):7456-7468. doi: 10.1128/JVI.00685-16. Print 2016 Aug 15.

7.

Generation and Characterization of Monoclonal Antibodies against a Cyclic Variant of Hepatitis C Virus E2 Epitope 412-422.

Sandomenico A, Leonardi A, Berisio R, Sanguigno L, Focà G, Focà A, Ruggiero A, Doti N, Muscariello L, Barone D, Farina C, Owsianka A, Vitagliano L, Patel AH, Ruvo M.

J Virol. 2016 Jan 27;90(7):3745-59. doi: 10.1128/JVI.02397-15.

8.

Toward a hepatitis C virus vaccine: the structural basis of hepatitis C virus neutralization by AP33, a broadly neutralizing antibody.

Potter JA, Owsianka AM, Jeffery N, Matthews DJ, Keck ZY, Lau P, Foung SK, Taylor GL, Patel AH.

J Virol. 2012 Dec;86(23):12923-32. doi: 10.1128/JVI.02052-12. Epub 2012 Sep 19.

9.

Comprehensive linker-scanning mutagenesis of the hepatitis C virus E1 and E2 envelope glycoproteins reveals new structure-function relationships.

Rychlowska M, Owsianka AM, Foung SK, Dubuisson J, Bienkowska-Szewczyk K, Patel AH.

J Gen Virol. 2011 Oct;92(Pt 10):2249-61. doi: 10.1099/vir.0.034314-0. Epub 2011 Jun 22.

10.

Specific interaction of hepatitis C virus glycoproteins with mannan binding lectin inhibits virus entry.

Brown KS, Keogh MJ, Owsianka AM, Adair R, Patel AH, Arnold JN, Ball JK, Sim RB, Tarr AW, Hickling TP.

Protein Cell. 2010 Jul;1(7):664-74. doi: 10.1007/s13238-010-0088-9. Epub 2010 Jul 29.

11.

Mutations within a conserved region of the hepatitis C virus E2 glycoprotein that influence virus-receptor interactions and sensitivity to neutralizing antibodies.

Dhillon S, Witteveldt J, Gatherer D, Owsianka AM, Zeisel MB, Zahid MN, Rychłowska M, Foung SK, Baumert TF, Angus AG, Patel AH.

J Virol. 2010 Jun;84(11):5494-507. doi: 10.1128/JVI.02153-09. Epub 2010 Mar 17.

12.

Requirement of cellular DDX3 for hepatitis C virus replication is unrelated to its interaction with the viral core protein.

Angus AG, Dalrymple D, Boulant S, McGivern DR, Clayton RF, Scott MJ, Adair R, Graham S, Owsianka AM, Targett-Adams P, Li K, Wakita T, McLauchlan J, Lemon SM, Patel AH.

J Gen Virol. 2010 Jan;91(Pt 1):122-32. doi: 10.1099/vir.0.015909-0. Epub 2009 Sep 30.

13.

CD81 is dispensable for hepatitis C virus cell-to-cell transmission in hepatoma cells.

Witteveldt J, Evans MJ, Bitzegeio J, Koutsoudakis G, Owsianka AM, Angus AG, Keck ZY, Foung SK, Pietschmann T, Rice CM, Patel AH.

J Gen Virol. 2009 Jan;90(Pt 1):48-58. doi: 10.1099/vir.0.006700-0.

14.

Genotype-dependent sensitivity of hepatitis C virus to inhibitors of the p7 ion channel.

Griffin S, Stgelais C, Owsianka AM, Patel AH, Rowlands D, Harris M.

Hepatology. 2008 Dec;48(6):1779-90. doi: 10.1002/hep.22555.

PMID:
18828153
15.

Neutralizing host responses in hepatitis C virus infection target viral entry at postbinding steps and membrane fusion.

Haberstroh A, Schnober EK, Zeisel MB, Carolla P, Barth H, Blum HE, Cosset FL, Koutsoudakis G, Bartenschlager R, Union A, Depla E, Owsianka A, Patel AH, Schuster C, Stoll-Keller F, Doffoël M, Dreux M, Baumert TF.

Gastroenterology. 2008 Nov;135(5):1719-1728.e1. doi: 10.1053/j.gastro.2008.07.018. Epub 2008 Jul 22.

PMID:
18718838
16.

Broadly neutralizing human monoclonal antibodies to the hepatitis C virus E2 glycoprotein.

Owsianka AM, Tarr AW, Keck ZY, Li TK, Witteveldt J, Adair R, Foung SK, Ball JK, Patel AH.

J Gen Virol. 2008 Mar;89(Pt 3):653-9. doi: 10.1099/vir.0.83386-0.

17.

Identification of a broadly cross-reacting and neutralizing human monoclonal antibody directed against the hepatitis C virus E2 protein.

Perotti M, Mancini N, Diotti RA, Tarr AW, Ball JK, Owsianka A, Adair R, Patel AH, Clementi M, Burioni R.

J Virol. 2008 Jan;82(2):1047-52. Epub 2007 Nov 7.

18.

Determination of the human antibody response to the epitope defined by the hepatitis C virus-neutralizing monoclonal antibody AP33.

Tarr AW, Owsianka AM, Jayaraj D, Brown RJ, Hickling TP, Irving WL, Patel AH, Ball JK.

J Gen Virol. 2007 Nov;88(Pt 11):2991-3001.

PMID:
17947521
19.

Replication-competent recombinant vesicular stomatitis virus encoding hepatitis C virus envelope proteins.

Tani H, Komoda Y, Matsuo E, Suzuki K, Hamamoto I, Yamashita T, Moriishi K, Fujiyama K, Kanto T, Hayashi N, Owsianka A, Patel AH, Whitt MA, Matsuura Y.

J Virol. 2007 Aug;81(16):8601-12. Epub 2007 Jun 6.

20.

Cloning, expression, and functional analysis of patient-derived hepatitis C virus glycoproteins.

Tarr AW, Owsianka AM, Szwejk A, Ball JK, Patel AH.

Methods Mol Biol. 2007;379:177-97. Review.

PMID:
17502679
21.

Immunogenic and functional organization of hepatitis C virus (HCV) glycoprotein E2 on infectious HCV virions.

Keck ZY, Xia J, Cai Z, Li TK, Owsianka AM, Patel AH, Luo G, Foung SK.

J Virol. 2007 Jan;81(2):1043-7. Epub 2006 Nov 1.

22.

Identification of conserved residues in the E2 envelope glycoprotein of the hepatitis C virus that are critical for CD81 binding.

Owsianka AM, Timms JM, Tarr AW, Brown RJ, Hickling TP, Szwejk A, Bienkowska-Szewczyk K, Thomson BJ, Patel AH, Ball JK.

J Virol. 2006 Sep;80(17):8695-704.

23.

Characterization of the hepatitis C virus E2 epitope defined by the broadly neutralizing monoclonal antibody AP33.

Tarr AW, Owsianka AM, Timms JM, McClure CP, Brown RJ, Hickling TP, Pietschmann T, Bartenschlager R, Patel AH, Ball JK.

Hepatology. 2006 Mar;43(3):592-601.

PMID:
16496330
24.

Monoclonal antibody AP33 defines a broadly neutralizing epitope on the hepatitis C virus E2 envelope glycoprotein.

Owsianka A, Tarr AW, Juttla VS, Lavillette D, Bartosch B, Cosset FL, Ball JK, Patel AH.

J Virol. 2005 Sep;79(17):11095-104.

25.

Direct evidence that naturally occurring mutations within hepatitis B core epitope alter CD4+ T-cell reactivity.

Torre F, Cramp M, Owsianka A, Dornan E, Marsden H, Carman W, Williams R, Naoumov NV.

J Med Virol. 2004 Mar;72(3):370-6.

PMID:
14748060
26.

Analysis of antigenicity and topology of E2 glycoprotein present on recombinant hepatitis C virus-like particles.

Clayton RF, Owsianka A, Aitken J, Graham S, Bhella D, Patel AH.

J Virol. 2002 Aug;76(15):7672-82. Erratum in: J Virol 2002 Sep;76(18):9562.

27.

Functional analysis of hepatitis C virus E2 glycoproteins and virus-like particles reveals structural dissimilarities between different forms of E2.

Owsianka A, Clayton RF, Loomis-Price LD, McKeating JA, Patel AH.

J Gen Virol. 2001 Aug;82(Pt 8):1877-83.

PMID:
11457993
28.

Evidence for structural differences in the S domain of L in comparison with S protein of hepatitis B virus.

Clayton RF, Owsianka A, Patel AH.

J Gen Virol. 2001 Jul;82(Pt 7):1533-41.

PMID:
11413363
29.
30.
31.

Hepatitis C virus core protein interacts with a human DEAD box protein DDX3.

Owsianka AM, Patel AH.

Virology. 1999 May 10;257(2):330-40.

32.

Core variability does not affect response to interferon alpha in HBeAg negative chronic hepatitis B.

Alexopoulou A, Owsianka AM, Kafiri G, Dourakis SP, Carman WF, Hadziyannis SJ.

J Hepatol. 1998 Sep;29(3):345-51.

PMID:
9764979
33.

Role of the carboxy terminus of herpes simplex virus type 1 DNA polymerase in its interaction with UL42.

Marsden HS, Murphy M, McVey GL, MacEachran KA, Owsianka AM, Stow ND.

J Gen Virol. 1994 Nov;75 ( Pt 11):3127-35.

PMID:
7964622
34.

Inhibition of herpes simplex virus type 1 DNA polymerase activity by peptides from the UL42 accessory protein is largely nonspecific.

Owsianka AM, Hart G, Murphy M, Gottlieb J, Boehme R, Challberg M, Marsden HS.

J Virol. 1993 Jan;67(1):258-64.

35.

Advantages of branched peptides in serodiagnosis. Detection of HIV-specific antibodies and the use of glycine spacers to increase sensitivity.

Marsden HS, Owsianka AM, Graham S, McLean GW, Robertson CA, Subak-Sharpe JH.

J Immunol Methods. 1992 Feb 14;147(1):65-72.

PMID:
1541843
36.

Generation of anti-peptide and anti-protein sera. Effect of peptide presentation on immunogenicity.

McLean GW, Owsianka AM, Subak-Sharpe JH, Marsden HS.

J Immunol Methods. 1991 Mar 21;137(2):149-57.

PMID:
1707429
37.

Isolation and characterization of a high molecular weight lymphocyte Fc gamma receptor-blocking factor associated with renal allograft survival.

Sandilands GP, Cocker JE, McMillan MA, Owsianka AM, Marsden H, Junor BJ, Briggs JD, MacSween RN.

Clin Exp Immunol. 1990 Oct;82(1):140-4.

38.

Mapping of epitopes on the 65k DNA-binding protein of herpes simplex virus type 1.

Murphy M, Schenk P, Lankinen HM, Cross AM, Taylor P, Owsianka A, Hope RG, Ludwig H, Marsden HS.

J Gen Virol. 1989 Sep;70 ( Pt 9):2357-64.

PMID:
2476527
39.

Results of a large scale screen of microalgae for the production of protease inhibitors.

Cannell RJ, Kellam SJ, Owsianka AM, Walker JM.

Planta Med. 1988 Feb;54(1):10-4. No abstract available.

PMID:
3375330
40.

Microalgae and cyanobacteria as a source of glycosidase inhibitors.

Cannell RJ, Kellam SJ, Owsianka AM, Walker JM.

J Gen Microbiol. 1987 Jul;133(7):1701-5.

PMID:
3117966
41.

Alginate: a reversible semi-solid medium for investigating cell transformation.

Roscoe JP, Owsianka AM.

Br J Cancer. 1982 Dec;46(6):965-9. No abstract available.

Supplemental Content

Loading ...
Support Center